Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at HC Wainwright

HC Wainwright upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a neutral rating to a buy rating in a research report released on Tuesday morning, Marketbeat Ratings reports. They currently have $47.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q2 2024 earnings at $1.39 EPS, Q3 2024 earnings at $1.35 EPS, Q4 2024 earnings at $1.51 EPS, FY2024 earnings at $5.61 EPS and FY2025 earnings at $5.85 EPS.

Several other equities analysts have also recently issued reports on the company. StockNews.com cut Collegium Pharmaceutical from a strong-buy rating to a buy rating in a research note on Wednesday, May 1st. Piper Sandler cut Collegium Pharmaceutical from an overweight rating to a neutral rating and set a $39.00 target price on the stock. in a research note on Friday, May 10th. Needham & Company LLC cut Collegium Pharmaceutical from a buy rating to a hold rating in a research note on Friday, May 10th. Finally, Jefferies Financial Group raised Collegium Pharmaceutical from a hold rating to a buy rating and boosted their target price for the company from $41.00 to $44.00 in a research note on Friday, June 7th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $42.00.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $36.36 on Tuesday. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. Collegium Pharmaceutical has a fifty-two week low of $20.95 and a fifty-two week high of $40.95. The stock has a 50 day moving average price of $32.96 and a two-hundred day moving average price of $34.76. The company has a market capitalization of $1.19 billion, a P/E ratio of 15.15 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The company had revenue of $144.92 million during the quarter, compared to the consensus estimate of $147.04 million. Analysts expect that Collegium Pharmaceutical will post 5.69 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Colleen Tupper sold 19,710 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the sale, the chief financial officer now directly owns 130,845 shares of the company’s stock, valued at $4,476,207.45. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total value of $936,215.50. Following the sale, the director now directly owns 44,775 shares of the company’s stock, valued at $1,446,232.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the completion of the sale, the chief financial officer now directly owns 130,845 shares in the company, valued at $4,476,207.45. The disclosure for this sale can be found here. Insiders have sold a total of 105,502 shares of company stock valued at $3,540,796 over the last ninety days. Company insiders own 3.98% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the stock. Caxton Associates LP bought a new stake in Collegium Pharmaceutical in the first quarter worth $1,730,000. BNP Paribas Financial Markets lifted its holdings in shares of Collegium Pharmaceutical by 119.6% during the fourth quarter. BNP Paribas Financial Markets now owns 146,543 shares of the specialty pharmaceutical company’s stock valued at $4,511,000 after purchasing an additional 79,823 shares in the last quarter. SummerHaven Investment Management LLC lifted its holdings in shares of Collegium Pharmaceutical by 1.1% during the fourth quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock valued at $1,048,000 after purchasing an additional 368 shares in the last quarter. Johnson Investment Counsel Inc. bought a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at $257,000. Finally, LSV Asset Management lifted its holdings in shares of Collegium Pharmaceutical by 188.7% during the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after purchasing an additional 248,751 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.